<DOC>
	<DOCNO>NCT02489448</DOCNO>
	<brief_summary>The purpose study address follow hypothesis : ( ) Anti-PD-L1 therapy MEDI4736 administer concomitantly weekly nab-paclitaxel follow MEDI4736 concomitant ddAC neoadjuvant chemotherapy induce high pathologic complete response ( pCR ) rate ( &gt; 55 % ) triple negative breast cancer historical pCR rate ( 30-40 % ) observe chemotherapy alone . ( ii ) MEDI4736 safely co-administered full dose sequential nab-paclitaxel ( 100mg/m2 ) ddAC ( 60 mg/m2 600 mg/m2 respectively ) .</brief_summary>
	<brief_title>Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel Dose-dense AC Stage I-III Triple Negative Breast Cancer</brief_title>
	<detailed_description>The primary objective Phase I portion trial ass safety MEDI4736 combine chemotherapy determine full dose MEDI4736 administer concomitantly full dose weekly nab-paclitaxel follow dose-dense AC chemotherapy , respectively . The primary objective Phase II portion study estimate pCR rate MEDI4736 combination weekly nab-paclitaxel x 12 treatment follow MEDI4736 combination ddAC x 4 treatment estrogen receptor ( ER ) , progesterone receptor ( PR ) HER2 negative ( triple negative , TNBC ) , clinical stage I-III breast cancer . Pathologic complete response define absence residual invasive cancer hematoxylin eosin evaluation resect breast specimen sample regional lymph node follow completion neoadjuvant systemic therapy ( i.e . ypT0/Tis ypN0 ) . Secondary objective include : assess safety toxicity add anti-PD-L1 antibody , MEDI4736 standard care neoadjuvant chemotherapy Phase II portion trial . The study also monitor event special clinical interest suspect auto-immunologic etiology include grade â‰¥3 colitis , hyperthyroidism , hypophysitis , hypothyroidism , pneumonitis , rash anti-drug-antibody ( ADA ) immune complex disease ( manifest symptom arthralgias , abdominal pain , back pain , vasculitis ) . Exploratory objective include : assess correlation response therapy immune parameter tumor baseline post-treatment patient residual cancer therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Newly diagnose histologically confirm stage IIII , ER , PR HER2 negative invasive breast cancer define ASCO CAP guideline systemic chemotherapy would indicate base physician judgment follow standard NCCN practice guideline . 2 . Willing able provide write informed consent voluntary participation trial . 3 . Willing undergo baseline tumor core needle biopsy blood draw correlative science study . 4 . Eighteen year age old day signing inform consent . 5 . Female subject must either nonreproductive potential must negative urine serum pregnancy test upon study entry . 6 . Patients adequate organ function tolerate chemotherapy , define : peripheral granulocyte count &gt; 1,500/mm3 platelet count &gt; 100,000/mm3 hemoglobin &gt; 9 g/dL total bilirubin &lt; 1.5 x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 1.5 x ULN serum creatinine &lt; 1.5 x ULN serum creatinine clearance &lt; 50mL/min INR/PT/PTT &lt; 1.5 x ULN TSH within normal limit 1 . Patients underwent partial excisional biopsy lumpectomy , segmental mastectomy modify radical mastectomy sentinel node . 2 . Patients anthracycline , paclitaxel antibody therapy contraindicate . 3 . Patients active autoimmune disease document autoimmune disease within 2 year . Patients hypothyroidism clinically stable normal TSH level hormone replacement , patient vitiligo psoriasis require treatment remain eligible study . 4 . Active prior document inflammatory bowel disease ( Crohn 's disease , ulcerative colitis ) . 5 . Patients know active hepatitis B C HIV infection history tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>